

Press release  
April 30, 2008  
Gothenburg, Sweden

## Report from Annual General Meeting

At Vitrolife's Annual General Meeting yesterday, April 29, the following, amongst other things, was decided:

- No dividend will be paid for the financial year 2007.
- Re-election of Board members Patrik Tigerschiöld, Fredrik Mattsson, Madeleine Olsson-Eriksson and Semmy Rulf and new election of Tord Lendau and Maris Hartmanis, in accordance with the election committee's proposal.
- Authorization for the Board, for the time up until the next Annual General Meeting and on one or more occasions, to take a decision on the issue of a maximum of 1,950,000 shares in total, corresponding to approximately 9.8 percent of the company's share capital.
- The Board was authorized to take a decision, up until the next Annual General Meeting and on one or more occasions, with regard to the acquisition and transfer of the company's own shares, at the most 10 percent of the company's shares.
- The proposed principles for remuneration and other conditions of employment for the senior management were approved.
- The Board's proposal for a resolution concerning warrants to subscribe for new shares was approved. The warrants, maximum 400,000, are to be offered to employees of the Vitrolife Group.

At the Board meeting following election which was held after the Annual General Meeting, Patrik Tigerschiöld was elected Chairman of the Board.

April 30, 2008  
Gothenburg, Sweden  
The Board

**Queries should be addressed to:**

Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.  
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.

Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation. The Fertility product area works with nutrient solutions (media) and advanced one-time instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to maintain tissue in optimal condition outside the body for the required time while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.

Vitrolife today has approximately 140 employees and the company's products are sold in more than 80 markets. The head office is in Kungälv, Sweden, and there are subsidiaries in Sweden, USA, Australia and Italy. The Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.

---

Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungälv, Sweden. Corporate identity number 556354-3452.  
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Homepage: [www.vitrolife.com](http://www.vitrolife.com).

The information in this press release is such as that which Vitrolife is required to publish in accordance with the Securities Exchange and Clearing Operations Act.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.